Flow Cytometry Improved Updated Spectral Analyzer
|
By LabMedica International staff writers Posted on 31 Oct 2019 |

Image: The Aurora advanced flow cytometry system is now available with five lasers to enable seeing more than 30 colors from a single sample (Photo courtesy of Cytek Biosciences).
Flow cytometry aims to count the number, size, granularity, and other properties of cells in a heterogeneous population. Standard flow cytometry lasers excite certain fluorescent markers (fluorochromes, antibodies, or stains) on a cell as it passes through the beam.
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Latest Technology News
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Dementia and Alzheimer’s disease often develop silently over many years before symptoms appear. Detecting risk earlier could allow preventive strategies to begin long before memory problems interfere with... Read more
Serial Liquid Biopsies Reveal Therapy Resistance in Metastatic Prostate Cancer
Metastatic Prostate cancer can rapidly adapt under treatment, making it difficult to detect resistance before clinical progression. Genomic results from archival tumor tissue may no longer reflect the... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreIndustry
view channel
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more








